news
-
21 September 2020Axonics® Receives Health Canada Approval of Next Generation Implantable Neurostimulator
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announced that Health Canada has approved its next generation rechargeable implantable neurostimulator (INS) for the Axonics r-SNM® System.
The next generation INS approved by Health Canada reduces how frequently a patient needs to recharge their implanted device to once a month for about one hour. Axonics received U.S. FDA approval for this version of its INS in April 2020. Health Canada previously approved the first generation Axonics r-SNM System in January 2017. Axonics is currently the only rechargeable SNM system available in Canada.
“This approval is welcome news for patients in Western Canada suffering from bladder and bowel dysfunction, and reinforces the notion that Axonics is committed to providing the latest technology to all of its customers,” said Gary J. Gray, M.D., FRCS, a urologist and clinical professor at the Kipnes Urology Centre in the Department of Surgery at the University of Alberta. “We have implanted over 85 Axonics SNM devices in our center prior to the pandemic and have achieved clinical results that have exceeded our expectations. There is significant unmet need for sacral neuromodulation therapy in Western Canada and we have barely scratched the surface of fulfilling this demand. We look forward to continuing our relationship with Axonics for many years to come.”
Raymond W. Cohen, CEO of Axonics, said, “Physician and patient response to our next generation INS has been exceptional since it began shipping to U.S. customers in August. This approval from Health Canada demonstrates our commitment to support Canadian patients who can now benefit from the latest SNM technology. Axonics will continue to invest in innovation and enhancing the patient experience, and given the exceptional clinical results being generated, we are confident our efforts will accrue to SNM becoming the preferred therapy for overactive bladder and bowel dysfunction patients in North America.”
Related
Axonics® Reports 2-Year Clinical Results from ARTISAN-SNM Pivotal Study
NICE Recommends Axonics® r-SNM System for Treating Overactive Bladder
Axonics® Reports Second Quarter 2020 Results
Axonics® Announces 2-Year Topline Clinical Results from ARTISAN-SNM Pivotal Study
Axonics® Reports Preliminary Second Quarter 2020 Revenue
Axonics® Receives FDA Approval for 3T Full-Body MRI Scans
Axonics® Reports First Quarter 2020 Results
Axonics® Announces Fourth Quarter and Fiscal 2019 Financial Results
Axonics® Sacral Neuromodulation System Receives Reimbursement Approval in Germany
Axonics® Announces FDA Approval of Enhanced Neurostimulator Programmer
Axonics® Announces Preliminary Fourth Quarter and Full Year 2019 Revenue
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sanford Health Now Implanting Axonics® Sacral Neuromodulation Systems
Axonics® Announces Pricing of Public Offering of Common Stock
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
Axonics® Announces Second Quarter 2019 Financial Results and Operational Update
Axonics® Announces 1-Year Top-Line Clinical Results from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of ARTISAN Clinical Study Results in the Journal of Urology
Axonics® Announces First Quarter 2019 Financial Results and Operational Update
Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update
Axonics® Announces Positive Top-Line Clinical Data from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of NICE Briefing
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Axonics® Receives Health Canada Approval for its Sacral Neuromodulation External Trial System
Axonics® Announces Closing of Initial Public Offering of Common Stock
Axonics Modulation Technologies, Inc. Announces Pricing of Initial Public Offering of Common Stock
Axonics® Receives Technology Innovation Award from Medtech Insight
Axonics® Receives CE Mark for its Sacral Neuromodulation External Trial System
Axonics® Completes Enrollment of U.S. FDA Pivotal Study for its Sacral Neuromodulation System
Axonics Announces $40 Million Financing
Axonics® Sacral Neuromodulation System Receives Marketing Approval in Australia
Axonics® Granted Seven New U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics® Appoints Dr. Karen L. Noblett as Chief Medical Officer
Axonics Announces $20.5 Million Second Closing of its Series C Financing
Axonics Announces $14.5 Million First Close of Series C Financing
Axonics Granted Four U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics Sacral Neuromodulation System Receives Marketing Approval from Health Canada
Axonics Granted New U.S. Patent Related to its Implantable Neuromodulation Technology
Axonics Sacral Neuromodulation System™ Receives MRI Conditional Labeling
Axonics Announces First Patients Treated in Sacral Neuromodulation Study
Axonics Granted Six U.S. Patents Related to its Implantable Neuromodulation Technology
Axonics Modulation Technologies Announces $38.5 Million Series B Financing